Skip to main content
PODD
NASDAQ Industrial Applications And Services

Insulet beats Q2 revenue estimates but trims full-year growth outlook amid type 2 scaling hurdles

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$147.6
Mkt Cap
$11.555B
52W Low
$138.79
52W High
$354.88
52W Position info
6.3% above low
Off High info
58% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PODD is trading near its 52-week low of $138.79 (6.3% above the low).

Summary

Insulet posted Q2 revenue of $802M, exceeding guidance, but lowered its full-year growth forecast on slower type 2 diabetes scaling, delivering a mixed signal to investors.

Updates

  1. · Reuters — Shares fell over 12% pre-market following the guidance cut.


Key Events · Earnings and Guidance · PODD

  • Q2 Revenue Beats, Profit Surges

    Revenue reached $801.7M, a 23.5% year-over-year increase that exceeded the high end of guidance (20–22% constant currency). Adjusted EPS of $1.66 rose 41.5% from the prior year, fueled by robust Omnipod demand and expanding margins.

  • Full-Year Guidance Cut

    Full-year 2026 revenue growth guidance was lowered to 20–22% constant currency from 21–23%, with U.S. Omnipod growth now seen at 17–19% versus the previous 20–22%, reflecting lessons learned from scaling in type 2 diabetes.

  • Type 2 Scaling Challenges

    CEO Ashley McEvoy noted that the updated outlook captures 'what we're learning as we scale in type 2,' signaling near-term headwinds in this critical growth market, though long-term conviction remains intact.

  • Product Launches and Pipeline Progress

    Omnipod 5 launched in Spain, its 20th country, alongside a next-generation algorithm compatible with FreeStyle Libre 3 Plus. At ADA 2026, positive data from the STRIVE and EVOLUTION studies were presented, bolstering the case for Omnipod 6 and fully closed-loop technology.


Analysis · PODD · Industrial Applications And Services

A strong second quarter saw revenue climb 23.5% to $802M, topping the high end of guidance, while adjusted EPS jumped 41.5% to $1.66. Yet the company lowered its full-year revenue growth forecast to 20–22% from 21–23%, driven by a sharper reduction in U.S. Omnipod growth expectations—now 17–19% versus the prior 20–22%—as it navigates the complexities of scaling in the type 2 diabetes market. For an $11.6B med-tech stock, this beat-and-raise quarter overshadowed by a guidance cut is precisely the kind of mixed catalyst that moves shares. The revised outlook speaks directly to the key investor debate around the type 2 opportunity, and the market's reaction will depend on whether it rewards the strong current execution or penalizes the tempered near-term trajectory.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PODD was trading at $147.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $138.79 to $354.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PODD - Latest Insights

PODD
Nov 04, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $165.02
Real-time Price: $133.10 info
Change: -$31.92 (-19%) info
Market Cap: $9.238B info
PODD
Nov 04, 2026, 2:21 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $162.27
Real-time Price: $133.10 info
Change: -$29.16 (-18%) info
Market Cap: $9.238B info
PODD
Nov 04, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $155.77
Real-time Price: $133.10 info
Change: -$22.67 (-15%) info
Market Cap: $9.238B info
PODD
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $155.77
Real-time Price: $133.10 info
Change: -$22.67 (-15%) info
Market Cap: $9.238B info
PODD
Aug 05, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $144.52
Real-time Price: $133.10 info
Change: -$11.42 (-8%) info
Market Cap: $9.238B info